公开(公告)号：US20240092773A1

公开(公告)日：2024-03-21

申请号：US17786387

申请日：2020-12-22

Applicant: UCB Biopharma SRL

Inventor： Timothy John NORMAN ,  Zhaoning ZHU ,  Selvaratnam SUGANTHAN ,  Konstantinos RAMPALAKO ,  James MADDEN ,  Jag Paul HEER ,  Richard Jeremy FRANKLIN ,  Rickki Lee CONNELLY ,  Thierry DEMAUDE ,  Gregory William HASLETT ,  Benedicte LALLEMAND ,  Nathaniel Julius Thomas MONCK ,  Julian Hugh ROWLEY ,  Giancarlo TRANI

IPC: C07D471/04 ,  C07D401/14 ,  C07D217/02 ,  C07D401/12 ,  C07D237/30 ,  C07D403/12 ,  C07D403/14 ,  C07D491/04 ,  C07D401/04 ,  C07D413/14 ,  C07D417/12

CPC classification number: C07D471/04 ,  C07D401/14 ,  C07D217/02 ,  C07D401/12 ,  C07D237/30 ,  C07D403/12 ,  C07D403/14 ,  C07D491/04 ,  C07D401/04 ,  C07D413/14 ,  C07D417/12

Abstract: The present invention relates to dihydro-cyclopenta-isoquinoline derivatives of formula (I): processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular, disorders caused by the interaction of IgE with the FcεRI receptor.

公开(公告)号：US20230192646A1

公开(公告)日：2023-06-22

申请号：US17786300

申请日：2020-12-22

Applicant: UCB Biopharma SRL

Inventor： Timothy John NORMAN ,  Jag Paul HEER ,  Oliver PHILPS ,  William Ross PITT ,  James MADDEN ,  Zeshan YOUSUF

IPC: C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D471/04 ,  C07D215/06

CPC classification number: C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D471/04 ,  C07D215/06

Abstract: The present invention relates to dihydro-cyclopenta-isoquinoline derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FcεRI receptor.

公开(公告)号：US20210140972A1

公开(公告)日：2021-05-13

申请号：US17072665

申请日：2020-10-16

Applicant: UCB BIOPHARMA SRL

Inventor： James Philip O'CONNELL ,  John Robert PORTER ,  Alastair LAWSON ,  Boris KROEPLIEN ,  Stephen Edward RAPECKI ,  Timothy John NORMAN ,  David James MCMILLAN ,  Graham John WARRELLOW ,  Daniel Christopher BROOKINGS ,  Rikki Peter ALEXANDER

IPC: G01N33/68 ,  C07D401/14 ,  C07K14/525 ,  C07D471/00 ,  C07K14/705 ,  C07K16/24 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D471/04 ,  A61K47/64 ,  A61P37/00 ,  A61P35/00

Abstract: The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.

公开(公告)号：US20210088530A1

公开(公告)日：2021-03-25

申请号：US17013326

申请日：2020-09-04

Applicant: UCB BIOPHARMA SRL

Inventor： James Philip O'CONNELL ,  John Robert PORTER ,  Alastair LAWSON ,  Boris KROEPLIEN ,  Stephen Edward RAPECKI ,  Timothy John NORMAN ,  Graham John WARRELLOW ,  Tracy Lynn ARAKAKI ,  Alex Buntin BURGIN ,  William Ross PITT ,  Mark Daniel CALMIANO ,  David Andreas SCHUBERT ,  Daniel John LIGHTWOOD ,  Rebecca Jayne MUNRO

IPC: G01N33/68 ,  C07D401/14 ,  C07K14/525 ,  C07D471/00 ,  C07K14/705 ,  C07K16/24 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D471/04 ,  A61K47/64 ,  A61P37/00 ,  A61P35/00

Abstract: A new, stable trimeric TNFα structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNFα/TNFR1 interaction. Membrane-bound TNFα is not affected in its ability to signal through TNFR2, and thus the new structure of TNFα may be used in therapies which do not significantly raise the risk of infection or malignancy.

公开(公告)号：US20250012807A1

公开(公告)日：2025-01-09

申请号：US18818247

申请日：2024-08-28

Applicant: UCB BIOPHARMA SRL

Inventor： James Philip O'CONNELL ,  John Robert PORTER ,  Alastair LAWSON ,  Boris KROEPLIEN ,  Stephen Edward RAPECKI ,  Timothy John NORMAN ,  David James MCMILLAN ,  Graham John WARRELLOW ,  Daniel Christopher BROOKINGS ,  Rikki Peter ALEXANDER

IPC: G01N33/68 ,  A61K47/64 ,  A61P35/00 ,  A61P37/00 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D401/14 ,  C07D471/00 ,  C07D471/04 ,  C07K14/525 ,  C07K14/705 ,  C07K16/24

Abstract: The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.

公开(公告)号：US20230303517A1

公开(公告)日：2023-09-28

申请号：US17786394

申请日：2020-12-22

Applicant: UCB Biopharma SRL

Inventor： Timothy John NORMAN ,  Douglas BYRNE ,  Julian Hugh ROWLEY ,  Giancarlo TRANI ,  Konstantinos RAMPALAKOS ,  Nathaniel Julius Thomas MONCK ,  Benedicte LALLEMAND ,  Gregory William HASLETT ,  Rickki Lee CONNELLY ,  Jag Paul HEER ,  James MADDEN ,  Oliver PHILPS ,  Selvaratnam SUGANTHAN ,  Zeshan YOUSUF ,  Richard John MEARS

IPC: C07D401/14 ,  C07D221/06 ,  C07D401/12 ,  C07D405/14 ,  C07D413/14 ,  C07D409/12 ,  C07D498/10 ,  C07D471/04 ,  C07D417/12 ,  C07D413/12 ,  C07D487/04 ,  C07D405/12

CPC classification number: C07D401/14 ,  C07D221/06 ,  C07D401/12 ,  C07D405/14 ,  C07D413/14 ,  C07D409/12 ,  C07D498/10 ,  C07D471/04 ,  C07D417/12 ,  C07D413/12 ,  C07D487/04 ,  C07D405/12

Abstract: The present invention relates to dihydrocyclopenta-isoquinoline-sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FcεRI receptor.

公开(公告)号：US20230051300A1

公开(公告)日：2023-02-16

申请号：US17786295

申请日：2020-12-22

Applicant: UCB Biopharma SRL

Inventor： Timothy John NORMAN ,  Oliver PHILPS ,  Gregory William HASLETT ,  Jag Paul HEER ,  Giancarlo TRANI

IPC: C07D413/14 ,  C07D401/04 ,  C07D401/14 ,  C07D217/02 ,  C07D273/04 ,  C07D401/12

Abstract: The present invention relates to tetrahydrobenzo-isoquinoline sulfonamides derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FIERI receptor.

公开(公告)号：US20230194541A1

公开(公告)日：2023-06-22

申请号：US17823356

申请日：2022-08-30

Applicant: UCB BIOPHARMA SRL

Inventor： James Philip O'CONNELL ,  John Robert PORTER ,  Alastair LAWSON ,  Boris KROEPLIEN ,  Stephen Edward RAPECKI ,  Timothy John NORMAN ,  Graham John WARRELLOW

IPC: G01N33/68 ,  C07D401/14 ,  C07K14/525 ,  C07D471/00 ,  C07K14/705 ,  C07K16/24 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D471/04 ,  A61K47/64 ,  A61P37/00 ,  A61P35/00

CPC classification number: G01N33/6845 ,  C07D401/14 ,  C07K14/525 ,  C07D471/00 ,  C07K14/70575 ,  C07K16/241 ,  G01N33/6863 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D471/04 ,  G01N33/6854 ,  A61K47/6425 ,  A61P37/00 ,  A61P35/00 ,  G01N2500/02 ,  G01N2333/525 ,  C07K2317/55 ,  C07K2317/92

Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. Anew assay for identifying compounds with this mechanism of action is also disclosed.

公开(公告)号：US20230050670A1

公开(公告)日：2023-02-16

申请号：US17786309

申请日：2020-12-22

Applicant: UCB Biopharma SRL

Inventor： Timothy John NORMAN ,  Selvaratnam SUGANTHAN ,  Jag Paul HEER ,  Zeshan YOUSUF

IPC: C07D221/06 ,  C07D413/14

Abstract: The present invention relates to tetrahydrobenzo-isoquinoline sulfonamide derivatives of formula (1), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FcεRI receptor.